From Chairman Jin Yang-gon to Affiliate CEOs and Executives, HLB Group Leaders Join Share Purchases, Reflecting Confidence in Growth

Jin Yang-gon, Chairman, Adds Nearly 1 Million Shares in 43 Transactions Across Five Key Affiliates This Year
Kim Tae-han, Affiliate CEOs, and Executives Also Increase Holdings, Signaling Confidence in New Drug Business Growth

HLB Group executives and senior management have been purchasing shares of the group’s affiliates this year, signaling their confidence in the group’s growth prospects and corporate value.

According to the Financial Supervisory Service's electronic disclosure system on June 22, Jin Yang-gon, Chairman of HLB Group, has acquired approximately 1 million additional shares of key affiliates—including HLB Innovation, HLB Panagene, HLB Therapeutics, HLB Genex, and HLB Biostep—through 43 separate transactions since the beginning of this year.

In addition, Kim Tae-han, Head of Bio at HLB Group, participated in the affiliate share purchases by acquiring 210,000 shares of HLB Innovation.

Yoon Jong-sun, CEO of HLB Innovation, made his first share purchase since taking office, acquiring 3,000 shares on the open market. Kim Do-yeon, CEO of HLB Genex, purchased a total of 25,936 shares over two separate occasions this year, while CEO Kim Eui-jung also acquired an additional 11,000 shares.

Furthermore, Kim Kwang-jae, CEO of HLB Global, conducted an additional on-market purchase of 15,000 shares, and Shim Kyung-jae, CEO of HLB Pep, bought 2,170 shares.

Some affiliates have seen not only their CEOs but also other executives participate in share purchases. Baek Seong-jin, CEO of HLB Biostep, purchased an additional 5,000 shares, and two executives including Executive Director Lee Hyeong-seok acquired a combined total of 5,165 shares. At HLB Panagene, CEO Jang In-geun, Executive Director Choi Jae-jin, and three other executives purchased a total of 33,925 shares in recent transactions.

This collective participation of Chairman Jin Yang-gon, top management, affiliate CEOs, and key executives in share purchases reflects a shared perception that the current stock price is undervalued relative to corporate value, as well as their confidence in future business performance. Each of these factors has contributed independently to their decision to buy shares.

In particular, expectations for a corporate value re-evaluation are rising, as the second half of this year is set to bring major events such as the approval decision for new drugs targeting liver and bile duct cancer, as well as clinical trial results for key pipelines.

From the perspective of each affiliate, the timing coincides with the realization of major business achievements, and the management’s share purchases are interpreted as a demonstration of confidence in future growth potential.

An HLB Group representative stated, "The increased equity holdings by key management demonstrate the group’s internal trust in its new drug development initiatives and the growth strategies of each affiliate. We will do our utmost to prepare thoroughly for major events in the second half of the year and to ensure that the business achievements of each affiliate contribute to enhancing both corporate and shareholder value."

This content was produced with the assistance of AI translation services.